Literature DB >> 33964453

Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.

Gloria J Hong1, Sandra S Stinnett1, Sharon F Freedman2, David K Wallace3, S Grace Prakalapakorn4.   

Abstract

Guidelines on managing infants after initial anti-vascular endothelial growth factor (VEGF) treatment (eg, bevacizumab) for retinopathy of prematurity (ROP) are limited. We found that following initial bevacizumab treatment for ROP, prophylactically lasering infant eyes before hospital discharge reduced the number and duration of outpatient ROP screening examinations compared with following infants, per current United States (US) ROP screening guidelines.
Copyright © 2021 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2021        PMID： 33964453     DOI： 10.1016/j.jaapos.2021.02.002

Source DB:  PubMed          Journal:  J AAPOS        ISSN： 1091-8531            Impact factor:   1.220


  1 in total

1.  Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.

Authors:  Sharon F Freedman; Amra Hercinovic; David K Wallace; Raymond T Kraker; Zhuokai Li; Amit R Bhatt; Charline S Boente; Eric R Crouch; G Baker Hubbard; David L Rogers; Deborah VanderVeen; Michael B Yang; Nathan L Cheung; Susan A Cotter; Jonathan M Holmes
Journal:  Ophthalmology       Date:  2022-06-01       Impact factor: 14.277
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.